Perspective Therapeutics reports 2Q 2026 results, advances toward VMT-α-NET Phase 3

Perspective Therapeutics announced financial results and business updates for the quarter ended June 30, 2026, in a release dated August 10, 2026.

For its lead program, bamzireotide navoxetan (VMT-α-NET), the company reported that 76 patients with neuroendocrine tumors across four cohorts and one meningioma patient had been treated as of July 31.¹ The company said interim data presented at ASCO 2026 were consistent with prior findings and showed continued deepening of response,¹ with updated data expected at ESMO on October 23. Follow-up data from the 46 patients in Cohort 2 is expected to reach a threshold that the company said is expected to inform the Phase 3 study design¹ by late 2026, once all patients have had the chance for at least 60 weeks of monitoring.

The company said it is preparing for a Phase 3 study evaluating a proposed cumulative 20 mCi (740 MBq) dose administered in up to four treatments every eight weeks,¹ with site activation targeted around year-end 2026, subject to regulatory feedback and protocol finalization.¹

In its melanoma program, lapemelanotide zapixetar (VMT01), 27 patients had been enrolled across multiple dose cohorts, either as monotherapy or combined with nivolumab, as of July 31.¹ Data presented at ASCO 2026 showed two partial responses among seven patients treated with 3.0 mCi monotherapy, with safety data from all 27 patients showing the treatment was generally well tolerated.¹

For PSV359 in FAP-α-positive solid tumors, 17 patients had been treated across three dose cohorts as of July 31,¹ with the next clinical update planned in 2027.

On finances, the company reported cash, cash equivalents, and short-term investments totaling approximately $237 million as of June 30, 2026, up from about $145 million at the end of 2025, an amount it said it believes is sufficient to fund current planned clinical milestones and operational investments into late 2027.¹ Net loss for the quarter was $26.8 million, or $0.22 per basic and diluted share, compared with a net loss of $21.5 million, or $0.29 per share, in the same period a year earlier.¹